191 related articles for article (PubMed ID: 38072400)
1. Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer.
García E; Ayoub N; Tewari KS
J Gynecol Oncol; 2024 Jan; 35(1):e30. PubMed ID: 38072400
[TBL] [Abstract][Full Text] [Related]
2. Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials.
Monk BJ; Enomoto T; Kast WM; McCormack M; Tan DSP; Wu X; González-Martín A
Cancer Treat Rev; 2022 May; 106():102385. PubMed ID: 35413489
[TBL] [Abstract][Full Text] [Related]
3. Pharmacotherapy for the treatment of recurrent cervical cancer: an update of the literature.
D'Oria O; Bogani G; Cuccu I; D'Auge TG; Di Donato V; Caserta D; Giannini A
Expert Opin Pharmacother; 2024; 25(1):55-65. PubMed ID: 38159033
[TBL] [Abstract][Full Text] [Related]
4. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.
Boussios S; Seraj E; Zarkavelis G; Petrakis D; Kollas A; Kafantari A; Assi A; Tatsi K; Pavlidis N; Pentheroudakis G
Crit Rev Oncol Hematol; 2016 Dec; 108():164-174. PubMed ID: 27931835
[TBL] [Abstract][Full Text] [Related]
5. Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer.
Mutlu L; Tymon-Rosario J; Harold J; Menderes G
Expert Rev Anticancer Ther; 2022 Jun; 22(6):633-645. PubMed ID: 35533682
[TBL] [Abstract][Full Text] [Related]
6. Evolving standards and future directions for systemic therapies in cervical cancer.
Ang DJM; Chan JJ
J Gynecol Oncol; 2024 Mar; 35(2):e65. PubMed ID: 38282261
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.
O'Malley DM; Oaknin A; Monk BJ; Selle F; Rojas C; Gladieff L; Berton D; Leary A; Moore KN; Estevez-Diz MDP; Hardy-Bessard AC; Alexandre J; Opperman CP; de Azevedo CRAS; Randall LM; Feliu WO; Ancukiewicz M; Ray-Coquard I
Gynecol Oncol; 2021 Nov; 163(2):274-280. PubMed ID: 34452745
[TBL] [Abstract][Full Text] [Related]
8. The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer.
McLachlan J; Boussios S; Okines A; Glaessgen D; Bodlar S; Kalaitzaki R; Taylor A; Lalondrelle S; Gore M; Kaye S; Banerjee S
Clin Oncol (R Coll Radiol); 2017 Mar; 29(3):153-160. PubMed ID: 27838135
[TBL] [Abstract][Full Text] [Related]
9. Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition.
Minion LE; Tewari KS
Gynecol Oncol; 2018 Mar; 148(3):609-621. PubMed ID: 29666026
[TBL] [Abstract][Full Text] [Related]
10. Recurrent or primary metastatic cervical cancer: current and future treatments.
Gennigens C; Jerusalem G; Lapaille L; De Cuypere M; Streel S; Kridelka F; Ray-Coquard I
ESMO Open; 2022 Oct; 7(5):100579. PubMed ID: 36108558
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab for the treatment of cervical cancer.
Bizzarri N; Ghirardi V; Alessandri F; Venturini PL; Valenzano Menada M; Rundle S; Leone Roberti Maggiore U; Ferrero S
Expert Opin Biol Ther; 2016; 16(3):407-19. PubMed ID: 26796332
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
Coleman RL; Lorusso D; Gennigens C; González-Martín A; Randall L; Cibula D; Lund B; Woelber L; Pignata S; Forget F; Redondo A; Vindeløv SD; Chen M; Harris JR; Smith M; Nicacio LV; Teng MSL; Laenen A; Rangwala R; Manso L; Mirza M; Monk BJ; Vergote I;
Lancet Oncol; 2021 May; 22(5):609-619. PubMed ID: 33845034
[TBL] [Abstract][Full Text] [Related]
13. Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.
O'Malley DM; Neffa M; Monk BJ; Melkadze T; Huang M; Kryzhanivska A; Bulat I; Meniawy TM; Bagameri A; Wang EW; Doger de Speville Uribe B; Hegg R; Ortuzar Feliu W; Ancukiewicz M; Lugowska I
J Clin Oncol; 2022 Mar; 40(7):762-771. PubMed ID: 34932394
[TBL] [Abstract][Full Text] [Related]
14. Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer.
Bose CK
Med Oncol; 2022 Jan; 39(4):47. PubMed ID: 35092506
[TBL] [Abstract][Full Text] [Related]
15. Advances in immunotherapy for cervical cancer: recent developments and future directions.
Sherer MV; Kotha NV; Williamson C; Mayadev J
Int J Gynecol Cancer; 2022 Mar; 32(3):281-287. PubMed ID: 35256414
[TBL] [Abstract][Full Text] [Related]
16. Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929).
Da Silva DM; Enserro DM; Mayadev JS; Skeate JG; Matsuo K; Pham HQ; Lankes HA; Moxley KM; Ghamande SA; Lin YG; Schilder RJ; Birrer MJ; Kast WM
Clin Cancer Res; 2020 Nov; 26(21):5621-5630. PubMed ID: 32816895
[TBL] [Abstract][Full Text] [Related]
17. Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?
Vergote I; Ray-Coquard I; Lorusso D; Oaknin A; Cibula D; Van Gorp T
Expert Opin Investig Drugs; 2023 Mar; 32(3):201-211. PubMed ID: 36803278
[TBL] [Abstract][Full Text] [Related]
18. Advances in the Management of Recurrent Cervical Cancer: State of the Art and Future Perspectives.
Giudice E; Mirza MR; Lorusso D
Curr Oncol Rep; 2023 Nov; 25(11):1307-1326. PubMed ID: 37870697
[TBL] [Abstract][Full Text] [Related]
19. Top advances of the year: Cervical cancer.
Podwika SE; Duska LR
Cancer; 2023 Mar; 129(5):657-663. PubMed ID: 36609769
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy: an evolving paradigm in the treatment of advanced cervical cancer.
Eskander RN; Tewari KS
Clin Ther; 2015 Jan; 37(1):20-38. PubMed ID: 25592089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
